These findings confirm LLS30’s ability to bind to Gal-1 in MPNST cells, suggesting its potential as a Gal-1 inhibitor for therapeutic application in MPNSTs. This evidence concerns the gene LGALS1 and malignant peripheral nerve sheath tumor.